BackCymabay Therapeutics Overview

Cymabay Therapeutics Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$22.69M
39.82% YoY

As of Dec 31, 2023

Annual R&D Expenses (TTM)

$80.74M
18.75% YoY

Trailing 12 months ending Dec 31, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Cymabay Therapeutics (CBAY) FAQ

Stockcircle tracks research & development for Cymabay Therapeutics (CBAY), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Cymabay Therapeutics's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main CBAY overview so you can move from this figure to the surrounding analysis quickly.